common, with underestimation of blood loss and hyperkalaemia from transfusion of stored blood being the most common causes. Six of the medicationrelated arrests were associated with sevofluranerelated cardiovascular depression.
. To identify patient groups that might benefit from APC the authors considered it more rational to use their cited approach rather than have further formal appraisal of the drug. of APC [2] in the currently indicated high-risk population [3] .
This EMEA opinion, on the most rational way to proceed, reflects results of the trials requested by the FDA. The PROWESS follow-up trial showed no significant difference in the number of patients discharged home between APC and placebo groups [4] . The authors suggest that ENHANCE confirmed drug efficacy and safety. However, this has been seriously questioned: as a non-randomized, uncontrolled trial it was not designed to assess efficacy; compared with PROWESS the serious bleeding rates were greatly increased in ENHANCE (a NNT of 16 for a serious bleed) [5] . As the authors indicate, ADDRESS did not help APC and the drug's failure to demonstrate efficacy and safety in paediatric sepsis [6] raised further doubts around APC having any beneficial effect, even in adults [7] .
It may be a particular concern that the authors' data included a relatively high proportion of surgical patients (50%) vs. PROWESS (455/1690: 27%). Original Phase II and PROWESS trial data showed a higher mortality in the surgical patients randomized to APC [8] . A later retrospective reclassification of PROWESS patients may be difficult to interpret [9] . With treated surgical patients in ADDRESS also having a higher mortality, there is a consistent trend towards poorer outcome, with APC administration, in almost 1500 surgical patients enrolled to all three placebo controlled trials in adults. It may be hazardous to imply that APC has an acceptable benefit/risk profile in this group of patients.
Finally, data from a small number of hospitals in 2002-2005 may not reflect current UK practice. Following recent trial results use may now be very low as in other countries: recent French data (2006) showed that APC was not used in 14 of the 15 ICUs surveyed [10] . Low usage will probably persist unless new trials demonstrate clear benefit in easily identifiable patient groups.
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